PANews reported on March 7th, citing CoinDesk, that Bitcoin retreated after hitting $74,000 mid-week, falling approximately 3.7% in the past 24 hours and brieflyPANews reported on March 7th, citing CoinDesk, that Bitcoin retreated after hitting $74,000 mid-week, falling approximately 3.7% in the past 24 hours and briefly

Analysis: Bitcoin fell below $70,000, with short-term profit-taking and escalating tensions in the Middle East weighing on market sentiment.

2026/03/07 12:04
1 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

PANews reported on March 7th, citing CoinDesk, that Bitcoin retreated after hitting $74,000 mid-week, falling approximately 3.7% in the past 24 hours and briefly dipping below $70,000. Analysts believe this pullback primarily reflects profit-taking pressure from short-term traders, with some investors choosing to cash out after buying during the rebound. Despite the recent rebound, the market lacks sufficient confidence in the sustainability of the upward trend. Derivatives market sentiment is also pessimistic, with funding rates remaining significantly negative, indicating that traders are paying fees to maintain short positions, while spot demand remains. Recently, stablecoin inflows into exchanges have reached a new high since 2026, and spot Bitcoin ETFs have also seen net inflows again. The current market is clearly divergent, with institutional spot buying continuing to accumulate Bitcoin, while derivatives traders are constantly increasing their short positions. Historically, the simultaneous occurrence of spot accumulation and negative funding rates often triggers a "short squeeze," where short sellers are forced to close their positions, pushing prices upward. However, this outcome is not always guaranteed.

Market Opportunity
Notcoin Logo
Notcoin Price(NOT)
$0.0003689
$0.0003689$0.0003689
+2.44%
USD
Notcoin (NOT) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09